← Back to Search

minocycline hydrochloride for Anxiety Disorders

Phase 2
Waitlist Available
Led By Maryam Lustberg, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights

Study Summary

This trial studies if minocycline hydrochloride can help reduce depression and anxiety caused by chemotherapy in stage I-III breast cancer patients.

Eligible Conditions
  • Anxiety Disorders
  • Depression
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Center for Epidemiological Studies Depression Scale (CES-D) scores
Changes in the State Trait Anxiety Index (STAI) scores
Secondary outcome measures
Changes in Hamilton Anxiety Rating Scale scores
Changes in Hamilton Rating Scale for Depression scores
Changes in inflammatory blood markers
+1 more

Side effects data

From 2017 Phase 2 trial • 22 Patients • NCT01746043
20%
Peripheral Neuropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Armodafinil+Minocycline
Minocycline
Armodafinil

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm I (minocycline hydrochloride)Experimental Treatment3 Interventions
Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
Group II: Arm II (placebo)Placebo Group3 Interventions
Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minocycline
FDA approved

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
290,106 Total Patients Enrolled
3 Trials studying Anxiety Disorders
78 Patients Enrolled for Anxiety Disorders
Maryam Lustberg, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
4 Previous Clinical Trials
294 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
Maryam Lustberg 2015. "Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02203552.
All > Anxiety
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top